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An interview with Stefanie Dimmeler,
Chief Editor
In January, EMBO Molecular Medicine
named Stefanie Dimmeler the journal’s
ﬁrst academic Chief Editor. Stefanie
Dimmeler is Director of the Institute of
Cardiovascular Regeneration, Center for
Molecular Medicine at the University of
Frankfurt am Main (Germany) and she
already has great plans for the journal as
she details below.
EMBO Molecular Medicine: Could you
describe your background and ongoing
work?
SD:Aftercompleting myPhD inbiology,I
joined an experimental surgery division
at the University of Cologne to work on
clinically oriented projects involving
trauma and sepsis. I was later recruited
to establish the Division of Molecular
Cardiology in Frankfurt. Since then, I
have been investigating basic mechan-
isms of endothelial cell biology and
endothelial progenitor cells but also
tackling clinically oriented projects in
vascular biology. We have been focusing
on cell therapy approaches for the treat-
ment of ischemic heart disease and our
research culminated in ongoing clinical
trialsofcardiovascularrepairwithhuman
progenitor cells. More recently, we con-
centrated on microRNA-based therapeu-
tics for cardiovascular disease.
EMM: What are the main challenges
in translating basic ﬁndings to the
clinic?
SD: In the new ﬁeld of cell therapy,
gettingapprovalbyregulatoryauthorities
was time consuming. Moreover, we were
initially worried about the quality of cell
preparations in a routine setting and
performed extensive animal studies to
conﬁrm their functional activity. A major
challenge when we started the phase II
trial was funding. In comparison to basic
science, larger scale clinical trials are
extremely expensive, not only due to the
cost of patient treatment but also because
of patient insurance issues.
A further challenge for physicians is to
free time from their clinical duties so that
they can conduct translational work and
establish new concepts in clinical trials.
The generation of professional interdis-
ciplinary teams including PhDs working
in clinical departments also helps. In
contrast to the US, where it is common to
haveaparttimejobinresearchandinthe
clinic, in Europe this is not really
established.
EMM: Why did you become Chief Editor
of EMBO Molecular Medicine?
» ...I am dedicated to
translational medicine!«
SD: First, I hesitated to accept yet another
commitment. However, after meeting
with the editorial team and after a second
thought, I got enthusiastic. We need a
high quality journal that bridges the
worlds of basic and clinical science.
Linking the high reputation of EMBO in
the molecular biology world to high
quality clinical work and patient studies
is a very attractive way to succeed in this
aim. Given the achievements of EMBO
Molecular Medicine so far, I thought
that it is worth to put energy in this
endeavour—I am dedicated to transla-
tional medicine!
EMM: In your opinion, what are the
journal’s achievements?
SD: Overall, EMBO Molecular Medicine is
doing extremely well. The journal has a
fantastic team of experienced profes-
sional editors. The senior editors and
the advisory editorial board members
belong to the best scientists in the world
representing the different ﬁelds of mole-
cular medicine.
EMBO Molecular Medicine published
its ﬁrst issue in April 2009 and has since
established itself as a reliable source
of high quality translational research.
During the last two years, the journal
published several landmark papers in
a range of medically relevant areas,
including neurodegenerative diseases,
cancer research, RNAi-based therapeu-
tics, and inﬂammation. The papers
published in EMBO Molecular Medicine
have a very high impact already and
we are looking forward to the announce-
ment of our ﬁrst impact factor this
summer.
EMM: What are your future plans for
EMBO Molecular Medicine?
SD: My ﬁrst aim is to increase
the visibility of the journal: EMBO
MolecularMedicinebringstogetherbasic
molecular and clinical science and aims
to publish the best translational
research. EMBO traditionally is very
strong in molecular science, however,
it is not yet sufﬁciently established
in clinical science. We need to connect
these ﬁelds and make EMBO Molecular
Medicine better visible to the medical
community. For example, the journal
will organize an international confer-
ence (‘‘Molecular Insights for Innova-
tive Therapies’’, December 1–3, 2011)
featuring leaders in the ﬁeld of
molecular medicine and translational
sciences.
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i sa l r e a d yv e r ys t r o n gi ns o m e
medical disciplines such as cancer and
neurodegeneration and we will work
hard to attract more papers in ﬁelds
such as cardiovascular medicine, immu-
nology or infectious diseases. EMBO
Molecular Medicine has the vision to
be open for and to cover all medical
disciplines.
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